NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

You are talking about something trivial. Let's talk about something that really matters. I can still see that nonsense that ATL-DC is not DCVax-L still pops up.

Repeat after me word by word:

There is only one company on this planet that solely owns the technology that can make DCs present hundreds of tumor-associated peptides to immune system so that massive and sustainable t-cell infiltration into tumor site can be activated. That company is called $NWBO. It doesn't matter what kind of name was assigned to the DC vaccine. As long as the DC vaccine has the amazing efficacy, the core technology must come from $NWBO. This is what the science told me.

The following is something I posted before. Read it again.

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
https://clinicaltrials.gov/study/NCT03513952

2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
https://www.annalsofoncology.org/article/S0923-7534(23)01852-5/fulltext

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-1728/750533/A-Phase-II-Open-Label-Randomized-Clinical-Trial-of?redirectedFrom=fulltext

Conclusions:

Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the complete response rate, and durable responses exceeding 2 years. However, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.

Here is the paper about the trial on the combination of Provenge with rhIL-7. The rhIL-7 exhibited significant impact on the T cell counts and immune response. But without doubt, the combination of rhIL-7 with DCs educated and primed by NWBO's technology has the most amazing efficacy.

BTW, Martin A. Cheever was the study director. Was he on the SAB of NWBO before? Sadly he passed away a couple of years ago.

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8404457/

Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56bright natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/study/NCT01881867

Investigators
Principal Investigator:Lawrence Fong,Cancer Immunotherapy Trials Network
Study Director:Martin A. Cheever,Fred Hutchinson Cancer Research Center/Cancer Immunotherapy Trials Network

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
https://clinicaltrials.gov/study/NCT00923351

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
https://aacrjournals.org/clincancerres/article/22/13/3182/79179/Adjuvant-Immunotherapy-to-Improve-Outcome-in-High

Autologous tumor lysate, cell therapy, and CYT107
Tissue was obtained via percutaneous core needle biopsy and/or fine needle aspiration (n = 26) or surgical resection (n = 3).

Results: Forty-three patients enrolled and 29 received immunotherapy. The regimen was well tolerated. Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rhabdomyosarcoma vs. other sarcomas) and response to standard therapy (74% no residual disease vs. 0% residual disease). Five-year intent-to-treat OS of patients with newly diagnosed metastatic Ewing/rhabdomyosarcoma was 77%, higher than previously reported in this population and higher than observed in a similar group treated with an earlier adjuvant immunotherapy regimen (25% 5-year OS). T-cell responses to autologous tumor lysate were identified in 62% of immunotherapy recipients, and survival was higher in those patients (73% 5-year OS with vs. 37% without immune response, P = 0.017). Immune reconstitution, measured by CD4 count recovery, was significantly enhanced in subjects treated with recombinant human IL7.